Walsh Kendra L, Silva Christian R, Lee Patrick H
The Warren Alpert Medical School of Brown University (KLW), Providence, RI.
Pharmacy Services, Hasbro Children's Hospital, Lifespan (KLW, CRS, PHL), Providence, RI.
J Pediatr Pharmacol Ther. 2024 Dec;29(6):650-653. doi: 10.5863/1551-6776-29.6.650. Epub 2024 Dec 9.
Methemoglobinemia is a rare, yet life-threatening disorder that occurs due to an accumulation of methemoglobin in the blood. The clinical presentation often includes dyspnea, cyanosis, and hypoxemia that shows little improvement with the administration of supplemental oxygen. The US Food and Drug Administration (FDA) warns against the administration of benzocaine to those younger than 2 years of age and urges manufacturers to add a statement regarding the possible development of methemoglobinemia to the packaging of any products containing this ingredient. However, providers caring for pediatric patients should recognize that methemoglobinemia may occur in toddlers and children outside of the FDA's specific age warning window and must keep a broad differential for patients presenting with respiratory distress. The objective of this article is to highlight a case of a child subsequently found to have benzocaine-induced methemoglobinemia and emphasize the importance of pharmacists in an emergency medicine setting, particularly in the care of patients with uncommon acute conditions requiring lesser-known pharmacologic treatments.
高铁血红蛋白血症是一种罕见但危及生命的疾病,由于血液中高铁血红蛋白的积累而发生。临床表现通常包括呼吸困难、发绀和低氧血症,补充氧气后改善甚微。美国食品药品监督管理局(FDA)警告不要给2岁以下儿童使用苯佐卡因,并敦促制造商在任何含有该成分的产品包装上添加关于可能发生高铁血红蛋白血症的声明。然而,照顾儿科患者的医护人员应认识到,高铁血红蛋白血症可能发生在FDA特定年龄警告范围之外的幼儿和儿童中,对于出现呼吸窘迫的患者必须进行广泛的鉴别诊断。本文的目的是突出一个后来被发现患有苯佐卡因诱导的高铁血红蛋白血症的儿童病例,并强调药剂师在急诊环境中的重要性,特别是在护理患有需要鲜为人知的药物治疗的罕见急性病症的患者时。